Investigation and analysis of the clinical application of Perampanel in the Southeast of China

ObjectiveThe aim of this study was to investigate the clinical trials of Perampanel (PER) at the First Affiliated Hospital of Xiamen University (FAHXU). Recommendations have been developed for the use of Perampanel in clinical practice. DesignA retrospective single-center validation study. SettingA tertiary general hospital in Xiamen, a city located on the southeastern coast of China. ParticipantsA total of 831 prescriptions were included for 188 patients were treated with Perampanel. Outcome measuresRecord the patients medication, including the diagnosis of the patients disease, the dose, course of medication, and the combination of medication, analyze the characteristics of the drug population and the medication unreasonableness by comparing the drug instructions and referring to relevant literature and guidelines. ResultsPER was mainly used in Neurology. Epilepsy is the most common conditions prescribed. There were 119 cases of inconsistent drug indications, 56 inappropriate dosing frequency, 3 inconsistent dose, and 6 inconsistent dose adjustment intervals. ConclusionThere is an improper use of PER within the FAHXU. Greater attention should be paid to changes in patients condition and observation of discomfort following medication administration. Monitoring of PER use should be further enhanced. A rational drug evaluation system should be established to promote the rational use of PER. Article SummaryOur study was one of the few studies on the clinical use of Perampanel, especially in Southeast China. As a third-generation antiepileptic drug, data on the clinical rational drug use of Perampanel is limited in China. There were several limitations worth noting. Firstly, the data in our study were collected at only one institution, thus not covering a broader population from other regions. Clinical outcomes, including medication efficacy and adverse events, were not tracked in patients with irrational medication use. Strengths and limitationsOur study was one of the few studies on the clinical use of Perampanel, especially in Southeast China. As a third-generation antiepileptic drug, data on the clinical rational drug use of Perampanel is limited in China. There were several limitations worth noting. Firstly, the data in our study were collected at only two institutions, thus not covering a broader population from other regions. Clinical outcomes, including medication efficacy and adverse events, were not tracked in patients with irrational medication use.